Thalassemia| A Pipeline Analysis Report 2018| Technavio

Technavio has announced its latest pipeline analysis report on
the thalassemia
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat thalassemia.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180711005672/en/

Technavio has published a new report on the drug development pipeline for Thalassemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market.

THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME
ONLY: VIEW
MARKET SNAPSHOT BEFORE PURCHASING

Thalassemia: Market overview

Thalassemia is an inherited blood disorder in which the body produces an
abnormal form of hemoglobin. Hemoglobin is a protein in red blood cells
that carries oxygen. The disorder can lead to the excessive destruction
of red blood cells, thereby causing anemia. Thalassemia can be inherited
from one parent or both the parents.

According to a senior market research analyst at Technavio,
“Thalassemia is of two types, namely alpha-thalassemia and
beta-thalassemia. Alpha-thalassemia occurs when there is a loss of two
of the four alpha globin gene therapy variants from the body.
Beta-thalassemia occurs when there is a decrease in the production of
hemoglobin in the body.”

Thalassemia: Segmentation analysis

This market research report segments the thalassemia market based on
therapies employed (monotherapy and monotherapy/combination therapy),
RoA (oral, intravenous, subcutaneous, intraosseous, and unknown),
therapeutic modality (gene therapy, small molecule, protein, biological,
plant-derived, and unknown), targets for drugs under development (HSCs,
HbF, TGF-beta proteins, TMPRSS6, HDAC1/2, glycine reuptake, hepcidin,
iron, ferroportin, pyruvate kinase, and iron homeostatis), MoA (HbF
stimulator, TGF-beta protein regulator, TMPRSS6 inhibitor, glycine
reuptake inhibitor, iron chelator, hepcidin stimulator, ferroportin
stimulator, pyruvate kinase stimulator, cell replacement, gene transfer,
T lymphocyte replacement, and iron homeostatis), and recruitment status
(recruiting and active, not yet recruiting).

Monotherapy includes the use of a single drug to treat a disorder or a
disease. In the current pipeline, around 69% of the molecules that are
being investigated for the treatment of thalassemia are monotherapy.

In case of oral RoA, the delivery of the drug substances is done through
the mouth cavity. About 24.15% of the total molecules that are in the
current pipeline are expected to be administered orally.

LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST
A FREE SAMPLE REPORT

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180711005672/en/

Leave a Comment